Options Wonderland

[3xBuBu]

ANDS discussed in two
presentations at the conference:

On Sunday, October 31, 2010 at 3:00 pm Eastern Daylight Time, Eric Lawitz, M.D.,
a principal investigator of the study, will give an oral presentation titled,
"Safety and Antiviral Activity of ANA598 in Combination with Pegylated
Interferon alpha 2A Plus Ribavirin in Treatment-Naive Genotype-1 Chronic HCV
Patients." The slides will be available on the Company's website at
www.anadyspharma.com following conclusion of the presentation.

On Tuesday, November 2, 2010 at 7:00 am Eastern Daylight Time, Anadys will
present data in a poster titled, "IL28B Polymorphism and Kinetics of Antiviral
Activity for ANA598 in Combination with Pegylated Interferon alpha 2A Plus
Ribavirin in Treatment-Naive Genotype-1 Chronic HCV Patients." The poster will
be available on the Company's website at www.anadyspharma.com.